Dysbiosis is defined as the disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution [18]. A recent treatment used for IBD/IBS/dysbiosis is serum-derived bovine immunoglobulin/protein isolate (SBI), an oral medical food product enriched in immunoglobulins (>50% IgG, 5% IgM, and 1% IgA). This evidence concerns the gene CD40LG and irritable bowel syndrome.